FDG-PET Scan Response Guided Chemotherapy Strategy for Advanced Non-small Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01170923|
Recruitment Status : Unknown
Verified July 2010 by Asan Medical Center.
Recruitment status was: Active, not recruiting
First Posted : July 28, 2010
Last Update Posted : July 28, 2010
The usual response to chemotherapy is decided through the image change by computed tomography (CT), which is taken at least 6-9 weeks.
In order to predict the response to chemotherapy earlier, patients received FDG-PET scan at the first cycle of chemotherapy. Chemotherapy was guided by the metabolic response by FDG-PET scan.
|Condition or disease||Intervention/treatment||Phase|
|Non-small Cell Lung Cancer||Device: FDR-PET Device: CT||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Standard Chemotherapy Strategy Versus Changing Chemotherapy Strategy as to FDG-PET Response After 1st Cycle of Standard Chemotherapy for Advanced Non-small Cell Lung Cancer|
|Study Start Date :||September 2008|
|Estimated Primary Completion Date :||August 2010|
Experimental: FDG-PET guided
Chemotherapy regimen will be changed depending on metabolic response.
FDR-PET performed after 1 cycle of chemotherapy
Active Comparator: CT guided
Chemotherapy regimen will be changed depending on CT findings (RECIST).
CT performed after 3 cycles of chemotherapy
- change in response rate [ Time Frame: within 4 cycles ]The usual response rate of GenexolPM/Cisplatin chemotherapy is 30-40%. This trial will assess whether the changing chemotherapy strategy using FDG-PET can increase response rate by 15%.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01170923
|Principal Investigator:||Sang-We Kim, MD||Asan Medical Center|